CD4 WORKSHOP REPORT JULY 22, 2017
|
|
- Dorcas McKenzie
- 5 years ago
- Views:
Transcription
1 CD4 WORKSHOP REPORT JULY 22, 2017
2 TABLE OF CONTENTS Contents Introduction 1 Strengthening the interface between diagnostics and care treatment monitoring 2 Findings from the first regional CD4 workshop 4 MSF s advanced HIV disease package 5 Discussion 7
3 Introduction Rosanna Peeling, chair of the diagnostics at the London School of Hygiene & Tropical Medicine welcomed the participants to the workshop. She explained that the objective of the series of CD4 workshops organized by the International Diagnostics Centre (IDC) at the London School of Hygiene & Tropical Medicine (LSHTM) is to create awareness of the role of CD4 testing in the context of viral load (VL) scale up and in managing patients with advanced HIV disease; to share country situational analysis on viral load scale up and CD4 testing; and determine demand forecasts, funding and procurement needs for CD4 testing. Tom Denny from Duke University chaired the first session and highlighted that CD4 is an easy marker to measure and is especially critical as for staging of advanced HIV disease. He reminded the group that all tools (e.g. VL and CD4) are important for patient management. Page 1
4 Strengthening the interface between diagnostics and care treatment monitoring Lara Vojnov from the WHO provided an overview of the uses of CD4 testing. The need for CD4 testing for treatment eligibility is now less critical because of the WHO guidelines recommending all HIV positive patients initiate ART regardless of CD4 cell counts. However, priority should be given to individuals with <350 CD4 cells in order to access ART. CD4 testing to monitor treatment failure is also less critical now with the recommendation that viral load should be used to monitor treatment failure. Since 2013, viral load is the preferred method to monitor treatment failure. Where viral load is routinely available, CD4 testing can be stopped if an individual is stable on ART and virally suppressed. CD4 testing should be continued for patients who are unstable on ART. CD4 should still be used for treatment failure if viral load is not available. CD4 testing is useful for clinical management. CD4 should be performed at baseline and for those reentering care for risk assessment. Depending on the CD4 cell count, cryptococcal antigen and TB screening may be required if an individual s CD4 count is <100 cells. Simplified care can be considered for individuals who are stable and have a CD4 count of <200 cells. Even with the WHO recommending Treat All, 38% of patients who are initiating ART do so with advanced disease. This is even higher in low and middle-income countries and among men. Advanced disease is a persistent and ongoing problem - in South Africa, over 30% of people living with HIV have presented with advanced disease in the past 5 years. Advanced disease is defined as CD4 <200 cells or WHO stage 3 or 4; and all children under the age of 5. However, even though the WHO considers WHO stage 3 or 4 as advanced disease, a study from Kenya, Malawi, Zimbabwe, and Uganda found that almost half the people with CD4 cell counts <100 had WHO clinical stage 1 or 2, so clinical staging may not be very accurate in identifying individuals with advanced disease. The new WHO Advanced Disease Guidelines package of care is linked to CD4 thresholds as shown in Figure 1 below. Even with the WHO recommending Treat All, 38% of patients who are initiating ART do so with advanced disease. Advanced disease is defined as CD4 <200, yet most countries are not collecting data on CD4 thresholds. Access to CD4 testing has become increasingly difficult since countries started the treat all approach, primarily due to a lack of prioritization and funding. Page 2
5 Figure 1: CD4 thresholds and an advanced disease package of care. Most countries in sub-saharan Africa have significant capacity to continue CD4 testing to identify patients with advanced HIV disease. USAID is mapping where CD4 devices are located in order to better align diagnostic services with treatment and care. Some countries have decommissioned their traditional laboratory based CD4 devices and redistributing their point of care devices to ensure wider access. Based on the new CD4 thresholds in Figure 1, it may be time to consider a target product profile to help companies develop a cheap semi-quantitative CD4 device. There remains significant capacity for CD4 testing. Mapping exercises will help optimize diagnostic services with treatment and care. We need a cheap semi-quantitative CD4 device. Page 3
6 Findings from the first regional CD4 workshop Debi Boeras and Imelda Mahaka from the International Diagnostics Centre provided a brief update from the first Regional CD4 Workshop held on May 18-19, 2017 in Nairobi in partnership with KEMRI. Two additional Regional Workshops are planned for The next workshop will be in Lusaka, Zambia on August in partnership with CIDRZ and the last workshop is planned to coincide with ICASA in Abidjan, Cote d Ivoire on December 4 in partnership with IRESSEFF. The report from the Nairobi workshop can be found here. A questionnaire was sent to the five East African Community countries that participated in the Nairobi workshop (Burundi, Kenya, Rwanda, Tanzania and Uganda) prior to the workshop to better understand how they are currently using CD4 testing, the status of viral load scale-up, and instrument distribution and usage for both CD4 and viral load. The countries noted that the current role of CD4 testing is not clearly elucidated in the 2016 WHO Treatment Guidelines and access to CD4 testing has become increasingly difficult since countries started the treat all approach primarily due to a lack of prioritization and funding. The current CD4 instruments in country have high maintenance costs when factoring in the low utilization rates. Countries would like to see clear guidance from the WHO around advanced HIV disease and the role of CD4 testing. Additionally, countries would like to have access to tools that will help them with demand forecasting as well as data management through connectivity solutions. CHAI is currently working on a demand forecasting tool that will help formulate a more accurate global demand for CD4 testing and reagents. The forecasting will help build networks and map country needs to adapt existing networks. The tool can also be used for country budgets when discussing needs for patient management with funders and donors. An important consideration is that some of the existing devices in countries are coming to the end of their life cycle and most do not have maintenance contracts. Some countries like Kenya already have systems in place to monitor their viral load program, however most countries have very limited data on number of people with <200 CD4 cells. CD4 instruments will need to be connected in order to get these data. There was discussion on mortality rates when you do not test for CD4. It may be possible to use data from TB LAM and CrAg showing lives saved to demonstrate the benefits of CD4 testing as CD4 testing is required to determine eligibility for TB LAM and CrAg screening. Another participant felt that CD4 testing is going to be critical when dolutegravir is introduced as there will be an increased risk for immune reconstitution inflammatory syndrome (IRIS). Countries have shown lack of uptake of advanced disease tools due to lack of clear guidance for use and cost. A package of tools and services can support uptake through clearer guidance and improved pricing for bundling diagnostics with drugs. Page 4
7 MSF s advanced HIV disease package Naïve How are we going to identify patients with advanced HIV disease Well Naïve asymtomatic Need baseline CD4 and stage CD4 < 200/ 100 triggers package for advanced disease Late presenters Clinically unwell Naïve symtomatic Management of diagnosed OIs Referral as necessary Need baseline CD4 and stage If CD4 < 200/ 100 triggers package for advanced disease Emmanuel Fajardo from MSF presented on the advanced HIV disease package that they are currently using in their clinics. Median CD4 counts at ART initiation remains low, with about 30% receiving their HIV diagnosis when admitted with symptomatic disease and low CD4 cell counts. It is important to identify HIV disease earlier and HIV self-testing has increased HIV testing uptake. ART exposed Routine VL >1000 Asymptomatic Need TRIGGERED CD4 CD4 < 200/ 100 triggers package for advanced disease Treatment Failures/ interrupters symptomatic/ clinically failing Need TRIGGERED VL and CD4 CD4 < 200/ 100 triggers package for advanced disease VL > 1000 consider expedited switch if on ART for > 6 mths Data from a study in South Africa show that point of care CD4 testing accelerates ART initiation, however it did not have any effect on retention in care at 6 and 12 months. In fact, there were more people lost to follow up among people who received point of care CD4 testing. CD4 is still an important marker for people living with HIV. Baseline CD4 cell count remains the best diagnostic tool to assess a patient s immune and clinical status, the risk of opportunistic infections and guide clinical management, especially in patients with advanced disease. For patients who are ARTexperienced, CD4 testing can help guide clinical decisions if they are virologically failing ART or if they have not received treatment for some time. Data from two hospitals in Kinshasa show that people with advanced HIV disease have high mortality rates. Mortality rates were greater than 23%, with almost a third of the patients dying within two days of being admitted into the hospital. Globally, there are still about a million AIDS-related deaths a year. CD4 cell counts is especially important to screen for opportunistic infections and for the provision of cotrimoxazole prophylaxis as well as to provide adapted adherence support for people with <200 CD4 cell counts. Therefore, it is very important to identify patients with advanced disease. Several diagnostic tools are available for the management of advanced HIV disease. The TB-LAM test is a lateral flow assay and it is the only true point of care TB test on the market. It is a simple to use and inexpensive urine-based test and results are given in 25 minutes. TB-LAM has been extensively evaluated and is sensitive/specific for people with <100 CD4 cells. Uptake of TB-LAM has been extremely poor due to the lack of adoption in national guidelines and lack of interest from National TB programs. Due to the low sales of TB-LAM, production may be discontinued if uptake remains low. GeneXpert MTB/RIF provides rapid and accurate diagnosis of HIV-associated TB and rifampicin resistance TB and allows for rapid treatment initiation. Despite WHO recommendations, only a few countries are using Xpert MTB/RIF as the first test and continue to rely on sputum microscopy. Many National TB Page 5
8 Programs consider the $10 per test to be too expensive, especially considering additional costs of service and maintenance. Cepheid, the developers of GeneXpert, has delayed the launch of the POC Omni platform until the middle of 2018 The cryptococcal antigen (CrAg) lateral flow assay is a rapid and inexpensive test and has revolutionized the management of cryptococcal meningitis (CM). This test allows for decentralizing CrAg testing as well as large-scale screening so that fluconazole prophylaxis can be administered to those who are found to be CrAg positive. While more than 20 countries have adopted CrAg screening in their national guidelines, only a few actually have large screening programs. Although the test is inexpensive if bought directly from the company, some local distributors have added high markups making the test much more expensive. In order to further reduce mortality among people with advanced HIV disease, several new diagnostic tools will be needed for other high priority opportunistic infections. One important missing rapid diagnostic test is for pneumocystis pneumonia, a common opportunistic infection, which can be fatal if left untreated. Current technologies to diagnose pneumocystis are either too expensive or require laboratory instrumentation. Diagnostic tests for toxoplamosis, a high burden disease in sub-saharan Africa, and severe bacterial infections are also urgently needed. MSF has identified a package of priority diagnostics needed for the primary health care and hospital levels. The CHAI demand forecast tool will better determine global and country needs for CD4 and can also help countries budget for the advanced disease package to provide optimal patient management. The MSF advanced HIV disease package retains a baseline CD4 cell count to assess a patient s immune and clinical status, the risk of opportunistic infections and guide clinical management. Page 6
9 Discussion It was noted that as diagnostics and the number of point of care instruments increases in countries, it becomes increasingly important that connectivity solutions be implemented to monitor and link test results for improved patient management. There are also readers for lateral flow assays that can transmit data. Most countries do not currently track mortality in their programs so it will be challenging to report on advanced disease and advocate for improved guidelines and needed diagnostics without this data. Further, there is a need to look at advanced disease as an entire package of care rather than disease specific silos and programs (CM versus TB versus PCP etc.). Many of the participants felt that there was a need to establish an Advanced Disease consortium to focus on advocacy, regulatory issues and procurement. Additionally, the consortium can support countries with the implementation of the advanced disease guidelines and reduce the barriers to implementing an advanced disease package. The group felt that a package of essential diagnostics (and drugs) is the way forward given that hospitals often have difficulties maintaining supplies of the various diagnostics and drugs with different suppliers and distributors. A number of research questions were also identified: 1. How often do we need to do CD4 testing? Should it be based on clinical signs or guidelines/country capacity? 2. Can co-trimoxazole be safely discontinued? In light of growing concerns of antimicrobial resistance, can co-trimoxazole be discontinued in low burden malaria/bacterial disease areas versus high burden malaria/bacterial disease areas. 3. How long should fluconazole prophylaxis/pre-emptive treatment be continued? Countries have shown lack of uptake of advanced disease tools due to lack of clear guidance for use and cost. A package can support uptake with clearer guidance and pricing for bundled diagnostics with drugs. Advanced Disease package needs to be an entire package of care and not individual silos for diseases or programs. Connectivity is very much need with the advanced disease package for patient management - to manage diagnostics and treatment. Need to establish an Advanced Disease consortium to focus on advocacy, regulatory issues and procurement. The consortium can support with the implementation of the AD guidelines and package. Page 7
East Africa Regional CD4 Workshop: The Role of CD4 Testing During Viral Load Scale-Up
East Africa Regional Workshop: The Role of Testing During Viral Load Scale-Up 18-19 May 2017 Nairobi, Kenya 1 Background... 3 Strengthening the Interface between Diagnostics and Care... 3 Country Needs
More informationAdvanced HIV Disease / AIDS
Advanced HIV Disease / AIDS Technical Summary for Activists Gilles Van Cutsem, SAMU, MSF Objectives Why is increased investment in Advanced HIV Disease (AHD) / AIDS critical? What are the issues? What
More informationRapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012
Rapid Diagnostics CHAI Experience 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012 CHAI is working in 12 countries on HIV POC test implementation Kenya Tanzania Ethiopia Malawi Mozambique
More informationStrengthening Laboratory Systems for HIV Differentiated Service Delivery
ADVANCING THE LABORATORY PROFESSION AND NETWORKS IN AFRICA Strengthening Laboratory Systems for HIV Differentiated Service Delivery Anafi Mataka African Society for Laboratory Medicine AIDS 2018 Outline
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationAdvanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF
Advanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF Mozambique Mozambique Mozambique Mozambique Preventing mortality MSF hospital, Kinshasa,
More informationHIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
More informationChallenge - Advanced HIV in Antiretroviral- Experienced Patients. Esther C. Casas South African Medical Unit Medecins Sans Frontieres
Challenge - Advanced HIV in Antiretroviral- Experienced Patients Esther C. Casas South African Medical Unit Medecins Sans Frontieres The forgotten 4 th 90: HIV related mortality plateauing % of Advance
More informationUNITAID investments to innovate and scale up access to HIV diagnostics
UNITAID investments to innovate and scale up access to HIV diagnostics WHO Annual meeting with Diagnostic Manufacturers and Stakeholders 10 March 2016 Smiljka de Lussigny (HIV Diagnostics Programme Manager,
More informationPOINT OF CARE DIAGNOSTICS
ENSURING ACCESS TO POINT OF CARE DIAGNOSTICS IN DECENTRALISED HIV AIDS PROGRAMMES REQUEST FOR EXPRESSION OF INTEREST Technology : Point of Care HIV diagnostic and treatment monitoring devices for Early
More informationAccelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges
Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges George Siberry, MD, MPH OGAC Senior Technical Advisor for Pediatrics March, 2016 Compared to Adults, Children (
More informationBalancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011
Balancing investment in point of care diagnostics versus laboratory testing in low resource settings Workshop on TB and HIV Diagnostics Workshop on TB and HIV Diagnostics June 28, 2011 Complexity Delivery
More informationDiagnostic Procurement The Clinton Foundation HIV/AIDS Initiative
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative 28 October 2008 Geneva 1 CHAI Work in Diagnostics - Context Diagnostic Test Agreements - In 2002 when CHAI was formed, the price of many
More informationDifferentiated Care Improving Engagement and Retention in HIV Care. Meg Doherty, MD PhD MPH World Health Organization
Differentiated Care Improving Engagement and Retention in HIV Care Meg Doherty, MD PhD MPH World Health Organization Why differentiated care and how can it facilitate epidemic control Effects on linkage,
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationInvesting for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS
Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation
More informationWorld Food Programme (WFP)
UNAIDS 2016 REPORT World Food Programme (WFP) Unified Budget Results and Accountability Framework (UBRAF) 2016-2021 2 Contents Achievements 2 Introduction 2 Innovative testing strategies 2 Access to treatment
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS Scaling up Paediatric HIV Care Treatment in resource limited settings Dr Chewe Luo MMed(Paed); MTropPaed; PhD UNICEF Health Section Programme Division
More informationAfrican Society for Laboratory Medicine
African Society for Laboratory Medicine Strategic Planning for Scaling Up HIV Diagnostics for 90/90/90 WHO/UNAIDS MEETING WITH DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS March 10-11, 2016 Planning and Forecasts
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationSourcing of ARVs & HIV diagnostics. Procurement for Impact P4i
Sourcing of ARVs & HIV diagnostics Procurement for Impact P4i AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 September 2014 Global Fund: Procurement for Impact: P4i Our objective was straightforward:
More informationDiagnostics product development projects
Page 0 Diagnostics product development projects Smiljka de Lussigny Technical Officer, HIV UNITAID Copenhagen, 23 September 2013 Page 1 1 2 3 About UNITAID HIV diagnostics market UNITAID s current investment
More informationSummary of PEPFAR State of Program Area (SOPA): Care & Support
Summary of PEPFAR State of Program Area (SOPA): Care & Support Prepared by E. Michael Reyes, MD, MPH (Original SOPA is a 45 page document) Introduction: Care and Support refers to the broad array of non-art
More informationProjected Demand for HIV Diagnostic Tests
Projected Demand for HIV Diagnostic Tests John Stover, Yu Teng, Adebiyi Adesina, Eline Korenromp On behalf of the Diagnostics Forecasting Technical Working Group (CDC, CHAI, GFATM, PfSCM, UNAIDS, UNICEF,
More informationIntroduction to PAHWP-EAC-LSHTM Workshop on Assessment of Clinical Performance of in-vitro Diagnostics
Introduction to PAHWP-EAC-LSHTM Workshop on Assessment of Clinical Performance of in-vitro Diagnostics Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre
More informationWho Is Dying and Why? AIDS Mortality as a Progress Metric
Who Is Dying and Why? AIDS Mortality as a Progress Metric Sharonann Lynch HIV & TB Policy Advisor MSF Access Campaign 1 OUTLINE 1. Trends in mortality 2. Finding the RIPs among the LTFU 3. Who is dying
More informationAIDS at 25. Epidemiology and Clinical Management MID 37
AIDS at 25 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Regional HIV and
More informationProcurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationEvidence on the impact of POC testing for addressing pediatric HIV
Evidence on the impact of POC testing for addressing pediatric HIV J E N N I F E R C O H N, E G PA F J I L I A N A. S A C K S, C H A I AIDS2018 Satellite Session: Key Considerations and Implementation
More informationUNITAID. Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012
UNITAID Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012 Challenges Achievements WHO Prequalification UNITAID support for prequalification of medicines Since 2007 UNITAID support
More informationCare of HIV Infected People
Care of HIV Infected People Patrick Ndase, MD, MPH MTN Annual Meeting Marriott Key Bridge, Arlington, VA April 21-23, 2008 Why Care for HIV infected in such a meeting? Site Core Community Why Care for
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationChallenges and Access to Viral Load Testing in Africa: Example of Cote d Ivoire Christiane Adje-Toure, PhD Lab Branch Chief CDC-COTE D IVOIRE
Challenges and Access to Viral Load Testing in Africa: Example of Cote d Ivoire Christiane Adje-Toure, PhD Lab Branch Chief CDC-COTE D IVOIRE Outline 1. Introduction 2. Barriers to Scaling up Viral Load
More informationWHAT IS STAR? MALAWI ZAMBIA ZIMBABWE SOUTH AFRICA
UNITAID PSI WHAT IS STAR? The UNITAID/PSI HIV Self-Testing Africa (STAR) Project is a four-year initiative to catalyze the market for HIV self-testing (HIVST). The project will be implemented in two phases,
More informationPEPFAR and Treatment 2.0
PEPFAR and Treatment 2.0 World Health Assembly Treatment 2.0 Side Meeting May 19, 2011 Charles Holmes, MD, MPH Office of the US Global AIDS Coordinator President s Emergency Plan for AIDS Relief Drug Optimization
More informationCurrent challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya Current Challenges of Paediatric HIV Care What is Happening in the
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationFlour fortification in the ECSA region and an overview of ECSA standards
East Central and Southern African Health Community (ECSA-HC) Flour fortification in the ECSA region and an overview of ECSA standards Mofota Shomari Manager-Food and Nutrition Security Harmonization Workshop
More informationHealth Situation Room. Introduction to the Concept 2018
Health Situation Room Introduction to the Concept 2018 What is a Health Situation Room? Health Situation Room is an innovative data visualization platform, which allows decision makers and programme
More informationRESEARCH. All Photos: Eric Bond/EGPAF,2017
RESEARCH All Photos: Eric Bond/EGPAF,2017 The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a recognized global leader in the fight to end pediatric HIV/AIDS through research, advocacy, and delivery
More informationA Call to Action. Differentiated Service Delivery for Adults at High Risk of HIV Disease Progression
Differentiated Service Delivery for Adults at High Risk of HIV Disease Progression A Call to Action HIV LEARNING NETWORK The CQUIN Project for Differentiated Service Delivery Table of Contents Acknowledgements...
More informationAIDS at 30 Epidemiology and Clinical Epidemiology and Management MID 37
AIDS at 30 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Adults and children
More information1.0 BACKGROUND / PROJECT DESCRIPTION
TERMS OF REFERENCE (TOR) FOR A CONSULTANT TO PREPARE AND ORGANIZE A NATIONAL ACTION PLAN MEETING UNDER THE AFRICAN REGIONAL HIV GRANT REMOVING LEGAL BARRIERS. General Information Intervention: Work Description:
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More information2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
More informationRegional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model
Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model Background for the program development Problem areas Access to the whole HIV-care
More informationAMDS Partners and Stakeholders Meeting CHAI HIV Diagnostics Forecasting Overview th September, 2014
AMDS Partners and Stakeholders Meeting CHAI HIV Diagnostics Forecasting Overview 29-30 th September, 2014 Agenda Introduction Overview of Global Diagnostics Forecasting Overview of Country Forecasting
More informationTowards an AIDS Free Generation
Informal Board Meeting 18 January, 2011 Towards an AIDS Free Generation Craig McClure Chief, HIV and AIDS Achieving an AIDS-Free Generation UNAIDS Getting to Zero UNICEF MTSP The Unite for Children, Unite
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationThe Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT
The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT Peter McDermott Managing Director, CIFF 19 th Board meeting, Geneva 6 th May 2009 Investment Criteria Measurable...change
More informationDr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018
Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018 1 Number of young people living with HIV (aged 15 19 years) by mode of HIV acquisition, 25 countries,*
More informationPrevention targets & scorecard
Prevention targets & scorecard Context Three opportunities For the first time: Global programmatic targets (UN Political Declaration 2016) Translate into pragmatic country road map targets Country and
More informationCommunities Coping with Children Living with HIV and AIDS Bridging the Gap between the Ideal and the Reality
Communities Coping with Children Living with HIV and AIDS Bridging the Gap between the Ideal and the Reality Geoff Foster, (Ministry of Health, Zimbabwe) Rose Gunda, (Southern African AIDS Trust) Anna
More informationKenya Perspectives. Post-2015 Development Agenda. Tuberculosis
Kenya Perspectives Post-2015 Development Agenda Tuberculosis SPEAKERS Anna Vassall Anna Vassall is Senior Lecturer in Health Economics at the London School of Hygiene and Tropical Medicine. She is a health
More informationUnified Xpert MTB/RIF Forecasting Initiative
Photo: Riccardo Venturi Unified Xpert MTB/RIF Forecasting Initiative Wayne van Gemert WHO Global TB Programme, Geneva WHO ANNUAL MEETING WITH HIV DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS 11 March 2016
More informationCommon EQA Mistakes - A provider Perspective. Experience from East African Regional External Quality Assessment Scheme (EA-REQAS)
Common EQA Mistakes - A provider Perspective Experience from East African Regional External Quality Assessment Scheme (EA-REQAS) Overview of Amref Health Africa Leading health development INGO in Africa
More informationStart Free Stay Free AIDS Free progress report
Start Free Stay Free AIDS Free 217 progress report Copyright 217 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved. The designations employed and the presentation of the material
More informationICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30 20:30 Prof. Soudre Room Rainbow Towers Conference Centre. Twitter Hash Tag: #EIDInnovation
Optimizing Testing and Treatment of HIV-Exposed Infants: Creating Sustainable Markets for Point-of-Care Technologies within National Diagnostic Networks ICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30
More informationAidspan Review of a Study on the Costs and Health Impact of Continued Global Fund Support for Antiretroviral Therapy
An independent watchdog of the Global Fund, and publisher of Global Fund Observer P.O. Box 66869-00800, Nairobi, Kenya Web: www.aidspan.org Email: info@aidspan.org Phone: +254-20-418-0149 Fax: +254-20-418-0156
More informationOverview of HIV in West and Central Africa
Overview of HIV in West and Central Africa Serge Paul Eholié Affiliations: Département de Dermatologie-Infectiologie, UFR des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan Service des
More informationADOLESCENTS AND HIV:
Elizabeth Glaser Pediatric AIDS Foundation Until no child has AIDS. Photo by Eric Bond/EGPAF, 2015 ADOLESCENTS AND HIV: PRIORITIZATION FOR ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION PROGRAMS, ADVOCACY
More information: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
More informationICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30 20:30 Prof. Soudre Room Rainbow Towers Conference Centre. Organized by:
Optimizing Testing and Treatment of HIV-Exposed Infants: Creating Sustainable Markets for Point-of-Care Technologies within National Diagnostic Networks ICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30
More informationINH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific
INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific Thuy Le, MD DPhil Duke University School of Medicine, USA Oxford University Clinical Research Unit Hospital
More informationPROGRESS REPORT ON THE ROAD MAP FOR ACCELERATING THE ATTAINMENT OF THE MILLENNIUM DEVELOPMENT GOALS RELATED TO MATERNAL AND NEWBORN HEALTH IN AFRICA
5 July 2011 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-first session Yamoussoukro, Côte d Ivoire, 29 August 2 September 2011 Provisional agenda item 17.1 PROGRESS REPORT ON THE ROAD MAP FOR
More informationTargeting HIV Settings Through PEPFAR. Bill Coggin, OGAC PEPFAR Laboratory Technical Working Group
Targeting HIV Settings Through PEPFAR Bill Coggin, OGAC PEPFAR Laboratory Technical Working Group PEPFAR Laboratory Program is a Critical part of Health Systems Strengthening Mission: To support countries
More informationOpportunities for improvement
Are there opportunities to manage cryptococcal meningitis better? Signals High-quality evidence Nelesh Govender National Institute for Communicable Diseases Inclusion in guidelines Translation into clinical
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationADDRESSING LEGAL AND POLICY BARRIERS. To Effective HIV Prevention
ADDRESSING LEGAL AND POLICY BARRIERS To Effective HIV Prevention Elizabeth Benomar National HIV Programme Managers Consultation 21 July 2018 - Amsterdam Ten-point plan for accelerating HIV prevention at
More informationDifferentiated Service Delivery: Taking Innovative Delivery Models to Scale
Differentiated Service Delivery: Taking Innovative Delivery Models to Scale Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Outline The Promise of Differentiated Service Delivery (DSD) Scale-up
More informationHEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE?
HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE? Ganiyat Kikelomo OYELEKE FMCP Hepatologist & Gastroenterologist Lagos University Teaching Hospital, Nigeria. INTEREST 2018, KIGALI CONFERENCE
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationWorld Health Organization HIV/TB Facts 2011
World Health Organization HIV/TB Facts 20 Note: The facts and figures of the HIV/TB Facts 20 are drawn from WHO HIV and TB surveillance data from 200 and 2009, as referenced below. Why is tuberculosis
More informationThe new WHO global injection safety policy and campaign
The new WHO global injection safety policy and campaign B. Allegranzi, SDS, HIS WHO/USAID/PEPFAR hosted webinar 20 August 2015 Overuse of injections and unsafe injection practices worldwide in 2000 (1)
More informationTB and HIV co-infection including IRIS
TB and HIV co-infection including IRIS Richard Lessells SAHCS Conference 2018 Clinical scenario 1 36-year-old male Presents with cough, fever & weight loss HIV test positive (new diagnosis) Sputum Xpert
More informationAPPROACH TO GEOGRPAPHIC AND/OR POPULATION FOCUS:
Sowing Sowing seeds MACO seeds of Hope of Hope May 2015 Civil society priority recommendations to the 2015 Zimbabwe SDS We support the priority placed by the PEPFAR COP 2015 global guidance on epidemic
More informationThe CQUIN Learning Network Lighthouse ALUP and POC VL: Innovations and Experience
The CQUIN Learning Network Lighthouse ALUP and POC VL: Innovations and Experience Eric Auben Mtemang ombe Lighthouse Trust - Malawi July 17-19, 2017 Harare, Zimbabwe THE LIGHTHOUSE WHO recognized Centre
More informationUSING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa
USING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa INTEREST 2018 Kigali, Rwanda Emmanuel Njeuhmeli, MD, MPH, MBA Senior Medical Advisor
More informationAchieving the 3 rd 90 in PEPFAR-supported countries:
Center for Global Health Achieving the 3 rd 90 in PEPFAR-supported countries: What will it take? Is it enough? Elliot Raizes, MD Division of Global HIV and TB Centers for Disease Control and Prevention
More informationand the Working Group from the EMBO-AIDS Related Mycoses Workshop Institute of Infectious Disease and Molecular Medicine, University of Cape Town,
1 AIDS-related mycoses: the way forward Gordon D. Brown 1,2*, Graeme Meintjes 1, Jay K. Kolls 3, Clive Gray 1, William Horsnell 1 and the Working Group from the EMBO-AIDS Related Mycoses Workshop 1 Institute
More informationAdapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access -
Adapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access - Associate Professor, Bui Duc Duong, MD, Ph.D. Deputy Director General, Ministry of Health Socialist Republic of Viet Nam HIV
More informationLessons learned from the IeDEA West Africa Collaboration
Lessons learned from the IeDEA West Africa Collaboration François DABIS with the contribution of Didier Koumavi EKOUEVI INSERM U-897, Bordeaux, France, Programme PACCI, ANRS site, Abidjan, Côte d Ivoire
More informationBUDGET AND RESOURCE ALLOCATION MATRIX
Strategic Direction/Function ILO Strengthened capacity of young people, youth-led organizations, key service providers and partners to develop, implement, monitor and evaluate HIV prevention programmes
More informationProgress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa
SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary
More informationDorothy Mbori-Ngacha UNICEF
THE DOUBLE DIVIDEND Action to improve survival of HIV exposed infected and uninfected children in the era of emtct and renewed child survival campaigns Dorothy Mbori-Ngacha UNICEF Outline The Double Dividend
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationInnovative Approaches for Eliminating Mother-to-Child Transmission of HIV. Mon Mari Mon Visa : Men as Change Agents in Côte d Ivoire
Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV Mon Mari Mon Visa : Men as Change Agents in Côte d Ivoire 1 Optimizing HIV Treatment Access for Pregnant and Breastfeeding Women
More informationThe Financial Implications of Reaching Global Treatment and Prevention Goals CHAI slide warehouse
The Financial Implications of Reaching Global Treatment and Prevention Goals CHAI slide warehouse Clinton Health Access Initiative (CHAI) October 2, 2015 As we near global consensus toward test and offer
More informationUpdate on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot
More informationA smart and doable investment
90-90-90 A smart and doable investment As of December 2013 Adults and children living with HIV Adults and children newly infected Adult & child deaths due to AIDS 35.0 million [33.2 million 37.2 million]
More informationGlobal Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA, PhD (c) Director, Global Plan Secretariat www.zero-hiv.org
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationStrategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children
Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children Dr. Mark W. Young Senior Health Specialist UNICEF Programme Division New York September 24,
More informationWHERE DO WE GO FROM HERE?
WHERE DO WE GO FROM HERE? WHAT WILL BE REQUIRED TO ACHIEVE ZERO DEATHS FROM TUBERCULOSIS? SALMAAN KESHAVJEE, MD, PHD, SCM HARVARD MEDICAL SCHOOL BRIGHAM AND WOMEN S HOSPITAL PARTNERS IN HEALTH INTERNATIONAL
More information90% 90% 90% 30% 10% 5% 70% 90% 95% WHY HIV SELF-TESTING? PLHIV diagnosed PLHIV undiagnosed
WHY HIV SELF-TESTING? In 2014, the United Nations set bold new targets, calling on the global community to ensure that by 2020, 90% of all people living with HIV will know their HIV status, 90% of all
More information